NCT03248791

Brief Summary

Comparison will be conducted between continuous variable infusions of both drugs (Phenylephrine and Norepinephrine) with starting doses of 0.75 mcg/Kg/min and 0.1 mcg/Kg/min respectively for prophylaxis against Post-spinal hypotension during cesarean delivery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Aug 2017

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 10, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 14, 2017

Completed
6 days until next milestone

Study Start

First participant enrolled

August 20, 2017

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
9 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2022

Completed
Last Updated

September 27, 2021

Status Verified

September 1, 2021

Enrollment Period

4.5 years

First QC Date

August 10, 2017

Last Update Submit

September 22, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • incidence of post-spinal anesthesia hypotension

    Defined as the percentage of patients with decreased systolic blood pressure less than 80% of the baseline reading

    30 minutes after spinal anesthesia

Secondary Outcomes (7)

  • incidence of severe post-spinal anesthesia hypotension

    30 minutes after spinal anesthesia

  • incidence of severe delivery hypotension

    10 minutes after delivery

  • systolic blood pressure

    2 hours after subarachnoid block

  • diastolic blood pressure

    2 hours after subarachnoid block

  • heart rate

    2 hours after subarachnoid block

  • +2 more secondary outcomes

Study Arms (2)

Phenylephrine

ACTIVE COMPARATOR

Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure

Drug: PhenylephrineDrug: Bupivacaine

Norepinephrine

EXPERIMENTAL

Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure

Drug: NorepinephrineDrug: Bupivacaine

Interventions

Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.

Phenylephrine

Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.

Also known as: noradrenaline
Norepinephrine

Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg

Also known as: Marcaine
NorepinephrinePhenylephrine

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • full term
  • pregnant women
  • scheduled for cesarean section

You may not qualify if:

  • pre-ecpamsia
  • eclampsia
  • bleeding
  • cardiac dysfuction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo University

Cairo, Egypt

RECRUITING

MeSH Terms

Interventions

PhenylephrineNorepinephrineBupivacaine

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsAnilidesAmidesAniline Compounds

Study Officials

  • Ahmed Mukhtar, Professor

    Head of research committee section in anesthesia department

    STUDY DIRECTOR

Central Study Contacts

Ahmed Hasanin, Professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

August 10, 2017

First Posted

August 14, 2017

Study Start

August 20, 2017

Primary Completion

March 1, 2022

Study Completion

March 10, 2022

Last Updated

September 27, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations